Cytopia targeting protein kinases
Wednesday, 18 June, 2008
Melbourne biotech Cytopia (ASX: CYT) is to present data from its study on FMS inhibitors at the Protein Kinase Targets oncology conference in Boston next week.
This will be the first formal disclosure of data from the study, in which a series of compounds discovered by Cytopia were found to inhibit the function of microphages, key cells in the immune system which also mediate inflammatory reactions.
One of the potential applications of the compounds is as a treatment of rheumatoid arthritis. The compounds are also showing potential as an inhibitor of the cells that cause bone osteolysis in advanced cancer sufferers.
Exclusive colostrum intake may reduce risk of food allergies
Newborns who are exclusively fed colostrum in the first 72 hours following birth are five times...
Sunscreen and supplements can lower your vitamin D levels
People who use SPF50+ sunscreen daily are more likely to be vitamin D deficient, while taking...
Low-dose drug prevents diabetes progression in young people
A low dose of the immunomodulatory drug anti-thymocyte globulin (ATG) appears safe and effective...
